Yasuhide Miyoshi1,2, Hiroji Uemura1,2, Susumu Umemoto1, Kentaro Sakamaki3, Masataka Taguri2, Kazuhiro Suzuki4, Yasuhiro Shibata4, Naoya Masumori5, Tomohiko Ichikawa6, Atsushi Mizokami7, Yoshiki Sugimura8, Norio Nonomura9, Hideki Sakai10, Seijiro Honma11, Masaoki Harada12, Yoshinobu Kubota1. 1. Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. 2. Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan. 3. Department of Biostatistics and Epidemiology, Yokohama City University, Graduate School of Medicine, Yokohama, Japan. 4. Department of Urology, Gunma University Graduate School of Medicine, Maebashi, Japan. 5. Department of Urologic Surgery and Andrology, Sapporo Medical University School of Medicine, Sapporo, Japan. 6. Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan. 7. Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. 8. Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan. 9. Department of Urology, Osaka University Graduate School of Medicine, Osaka, Japan. 10. Department of Nephro-Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. 11. Department of Analytical Research, ASKA Pharma Medical Co. Ltd., Kawasaki, Japan. 12. Department of Urology and Pathology, Kanagawa Cancer Center, Asahi-ku, Yokohama, Japan.
Abstract
BACKGROUND: There is no consensus on blood adrenal androgen concentrations in men with different stages and pathological grades of prostate cancer. In this study, dehydroepiandrosterone (DHEA) concentrations in blood were examined by ultrasensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS). We analyzed the correlation between DHEA concentrations in blood and clinicopathological findings of prostate cancer. METHODS: We analyzed 196 men (mean age 70 years) with prostate cancer. The patients underwent systematic needle biopsy, and peripheral blood sampling was conducted for measurement of DHEA. DHEA concentrations in blood were determined using LC-MS/MS method. Patient age, serum prostate-specific antigen, prostate volume measured by ultrasound, and DHEA levels in blood were compared with Gleason score and clinical stage by multivariate analyses. RESULTS: Median value of PSA and prostate volume were 11.5 ng/ml and 27.7 ml, respectively. Median concentration of DHEA in blood was 1,506.4 pg/ml. There was no correlation between serum DHEA and clinical variables such as age, serum PSA, and prostate volume. In multivariate analysis, low serum DHEA levels in prostate cancer patients were significantly related to high Gleason score and advanced clinical stage. Serum PSA levels in prostate cancer patients were also significantly associated with high Gleason score and advanced clinical stage. High serum PSA and low serum DHEA levels were significantly associated with poor prognosis factors in men with hormone-naïve prostate cancer. CONCLUSIONS: DHEA concentrations in blood were examined by newly developed ultrasensitive LC-MS/MS. We confirmed that low serum DHEA levels in prostate cancer patients were related to high Gleason score and advanced clinical stage. These results suggest that serum DHEA level may be a useful prognostic factor in prostate cancer patients.
BACKGROUND: There is no consensus on blood adrenal androgen concentrations in men with different stages and pathological grades of prostate cancer. In this study, dehydroepiandrosterone (DHEA) concentrations in blood were examined by ultrasensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS). We analyzed the correlation between DHEA concentrations in blood and clinicopathological findings of prostate cancer. METHODS: We analyzed 196 men (mean age 70 years) with prostate cancer. The patients underwent systematic needle biopsy, and peripheral blood sampling was conducted for measurement of DHEA. DHEA concentrations in blood were determined using LC-MS/MS method. Patient age, serum prostate-specific antigen, prostate volume measured by ultrasound, and DHEA levels in blood were compared with Gleason score and clinical stage by multivariate analyses. RESULTS: Median value of PSA and prostate volume were 11.5 ng/ml and 27.7 ml, respectively. Median concentration of DHEA in blood was 1,506.4 pg/ml. There was no correlation between serum DHEA and clinical variables such as age, serum PSA, and prostate volume. In multivariate analysis, low serum DHEA levels in prostate cancerpatients were significantly related to high Gleason score and advanced clinical stage. Serum PSA levels in prostate cancerpatients were also significantly associated with high Gleason score and advanced clinical stage. High serum PSA and low serum DHEA levels were significantly associated with poor prognosis factors in men with hormone-naïve prostate cancer. CONCLUSIONS:DHEA concentrations in blood were examined by newly developed ultrasensitive LC-MS/MS. We confirmed that low serum DHEA levels in prostate cancerpatients were related to high Gleason score and advanced clinical stage. These results suggest that serum DHEA level may be a useful prognostic factor in prostate cancerpatients.
Authors: Jessica Whitburn; Srinivasa R Rao; Emma V Morris; Sho Tabata; Akiyoshi Hirayama; Tomoyoshi Soga; James R Edwards; Zeynep Kaya; Charlotte Palmer; Freddie C Hamdy; Claire M Edwards Journal: Sci Adv Date: 2022-02-25 Impact factor: 14.136